-
公开(公告)号：US20140213621A1
公开(公告)日：2014-07-31
申请号：US14180721
申请日：2014-02-14
发明人： A. Vania APKARIAN
IPC分类号： A61K31/42 , A61K31/198 , A61K45/06
CPC分类号： A61K31/42 , A61K31/198 , A61K31/365 , A61K45/06 , A61K2300/00
摘要： Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors.
摘要翻译： 通过向个体施用一定量的含有甘氨酸受体激动剂如D-环丝氨酸或GlyT-1甘氨酸转运蛋白拮抗剂如肌氨酸的治疗慢性疼痛的个体治疗慢性疼痛，其量有效治疗慢性疼痛 疼痛。 治疗剂还可以含有二级止痛剂，例如阿片制剂，NSAIDs或cox-2抑制剂。 止痛剂可以以含有至少两种不同止痛剂的可注射溶液形式的药物组合物配制，其中至少一种止痛剂是甘氨酸受体激动剂或GlyT-1甘氨酸转运蛋白拮抗剂。 合适的药物组合物含有D-环丝氨酸和/或肌氨酸，任选与阿片剂，NSAID或cox-2抑制剂组合。
-
公开(公告)号：US20220401391A1
公开(公告)日：2022-12-22
申请号：US17610025
申请日：2020-05-08
发明人： A. Vania APKARIAN
IPC分类号： A61K31/167 , A61K31/425 , A61K31/198 , A61K31/192 , A61P29/00
摘要： The present disclosure features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.
-
公开(公告)号：US20170143681A1
公开(公告)日：2017-05-25
申请号：US15341700
申请日：2016-11-02
发明人： A. Vania APKARIAN
IPC分类号： A61K31/428 , A61K31/192 , A61K31/167 , A61K31/198
CPC分类号： A61K31/428 , A61K31/167 , A61K31/192 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.
-
公开(公告)号：US11419857B2
公开(公告)日：2022-08-23
申请号：US16584103
申请日：2019-09-26
发明人： A. Vania Apkarian
IPC分类号： A61K31/428 , A61K31/198 , A61K31/192 , A61K31/167 , A61K45/06
摘要： The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.
-
公开(公告)号：US20200046687A1
公开(公告)日：2020-02-13
申请号：US16584103
申请日：2019-09-26
发明人： A. Vania APKARIAN
IPC分类号： A61K31/428 , A61K31/167 , A61K31/192 , A61K31/198
摘要： The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
